Kornimate/medical-research-clean huggingface dataset:
to exam the efficacy of oral health and mediterranean diet interventions in preventing cognitive decline among older adults with mild cognitive impairment

Conditions: Mild Cognitive Impairment (MCI); Oral Health; Mediterranean Diet

Summary: at present, many literatures have confirmed that the mediterranean diet has the effect of delaying cognitive degeneration in patients with mild cognitive impairment, and can also slow down the speed of brain atrophy. in addition to the highly respected mediterranean diet every year, several years of foreign research have found the maintenance of oral hygiene also has a significant relationship with the decline of cognitive function. the intervention of "oral hygiene" is a new intervention method that has started in recent years. oral health will affect the overall health status, physical function, diet and nutritional status of the elderly. in particular, older adults with poor oral health are more likely to suffer from mild cognitive impairment. the relationship between oral health and nutrition and overall health is inseparable. if the concept of healthy eating (mediterranean diet) recognized by the public is used and oral health education is involved at the same time. to allow patients with mild cognitive impairment to maintain oral health care in daily life, and to increase the knowledge of the mediterranean diet and try to follow the rules of the mediterranean diet, whether there is a more significant impact on these patients.

this trial is expected to enroll 120 subjects, which will be accepted by the relevant researchers who carry out this study. in the pre-test part, all subjects will receive the montreal intelligence test (moca) and mini intelligence examination (mmse) and collect medas-14 item, oral health assessment tool, ohat and evaluation data of taiwan frailty criteria of taiwan. after completing the 12-week oral health and mediterranean diet education intervention, all subjects will undergo post-test follow-up evaluation (moca, mmse, medas-14 item, ohat and frailty criteria), and all subjects will be assessed 12 weeks after the intervention the subjects were followed up with follow-up cognitive function tracking (moca, mmse, medas-14 item, ohat and frailty criteria). finally, all the data were statistically analyzed to study which of the individual measures and the combined measures had a more significant cognitive effect on mci patients.

Eligibility criteria:
inclusion criteria: 1. over or equal to 50 years old 2. cdr score is less than or equal to 0.5 or mmse score is 24-30 (including 24 and 30) 3. conscious/complaint of cognitive decline exclusion criteria: 1. dementia 2. acute and significant mental illness in the past three months 3. acute serious medical and surgical diseases in the past three months 4. symptoms of delusions, hallucinations or delirium in the past three months 5. severe visual and hearing impairment in the past three months 6. other conditions that make the patient unable to cooperate: such as not being suitable after screening, not signing the subject's consent form.
the central venous catheter related complications in critically ill patients

Conditions: Catheter Thrombosis; Catheter-Related Infections; Central Venous Catheter Related Bloodstream Infection; Central Venous Catheter Thrombosis

Summary: in this prospective clinical study, the researchers investigate the incidence of catheter-related thrombosis and catheter-related infection during indwelling central venous catheterization in critically ill patients, and analyzed the risk factors for catheter-related complications and the relationship between catheter-related thrombi and catheter-related infections. the sample size is about 500.

a prospective clinical trial is conducted. five hundred participants who need to place central venous catheters admit to the department of critical care medicine of zhujiang hospital,southern medical university from february 2019. ultrasound is used for screening catheter-related thrombosis, and catheter-related infections are diagnosed according to the guidelines for the diagnosis and management of intravascular catheter-related infections. the primary outcome is the incidence of catheter-related thrombosis and catheter-related infections. the primary exposure factors are age, gender, apache ii, rbc, hct, plt, fib, d-dimer, pct, blood glucose, anticoagulants, and vasoactive drugs, catheter type, tube placement, indwelling time, etc. descriptive analysis is used for the incidence of various complications. t-test or non-parametric statistical test is used for single factor analysis of risk factors, chi-square test or fisher's exact probability test is used for counting data. multivariate analysis of risk factors and the relationship between complications are analyzed by logistic regression. statistical analysis is performed with spss statistics version 20.

Eligibility criteria:
inclusion criteria: * age \> 18 years old and \<80 years old; * central venous catheter is required to be placed through the internal jugular vein, subclavian vein or femoral vein; * catheter placement is estimated to be ≥ 72 hours. exclusion criteria: * the central venous catheter has been placed before entering the department; * there is obvious trauma or infection at the site of implantation; * there is already a blood vessel thrombus in the site before implantation; * recently, deep vein thrombosis or catheter-related thrombosis has occurred.

Keywords: catheter thrombosis infection ultrasound risk factor
masitinib in the treatment of patients with severe uncontrolled asthma and elevated eosinophil levels

Conditions: Asthma

Summary: the purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.

masitinib is a selective tyrosine kinase inhibitor. it is known that activation of inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with c-kit, lyn and pdgfr kinase signaling pathways; all key targets of masitinib. this is a multicenter, double-blind, randomized, parallel-group (ascending dose titration of masitinib to 6.0 mg/kg/day and matching placebo), comparative study of oral masitinib in the treatment of patients with severe asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels. eligible patients will be treated during at least 48 weeks.

Eligibility criteria:
main inclusion criteria include: * patients with a physician diagnosis of persistent asthma for at least 12 months based on global initiative for asthma (gina) 2009 guidelines whose asthma is partially controlled or uncontrolled on inhaled corticosteroids (ics) / long-acting beta2-agonists (laba) combination therapy. * patient with elevated eosinophil level related to asthma at baseline: ≥0.15 k/ul or patient with eosinophil level ≥0.15 k/ul related to asthma demonstrated in the year prior to screening * non-smoker patient for at least one year and with a prior tobacco consumption \<10 packs/year main exclusion criteria include: * female patient who is pregnant or lactating * asthmatic patient still exposed to allergens or to triggering factors influencing asthma control * chronic obstructive pulmonary disease and/or other lung diseases impairing pulmonary function tests * within 12 weeks prior to screening, patient who received oral corticosteroids for any other reason than to treat severe asthma exacerbation (patients needing long term corticosteroids intake to control basal asthma condition) * patient with history of acute infectious sinusitis or respiratory tract infection within 4 weeks prior to screening visit * patient with active lung disease other than asthma (e.g. chronic bronchitis)

Keywords: severe persistent asthma eosinophil tyrosine kinase inhibitor
bioavailability of doravirine (mk-1439) experimental nano formulations in healthy adults (mk-1439-046)

Conditions: Human Immunodeficiency Virus-1 (HIV-1)

Summary: this study aims to evaluate and compare the relative bioavailability of different doravirine (mk-1439) experimental nano formulations (nfs) with that of a doravirine film coated tablet.


Eligibility criteria:
inclusion criteria: * healthy participants * have been a non-smoker and/or have not used nicotine or nicotine-containing products for at least approximately 3 months exclusion criteria: * is a pregnant or a nursing female * has a history of stroke, chronic seizures or major neurological disorder * has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * has a history of neoplastic disease (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease
the application of negative atrioventricular hysteresis in cardiac resynchronization therapy

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate the application of negative atrioventricular hysteresis (navh) to improve electrical synchrony in cardiac resynchronization therapy (crt) patients.


Eligibility criteria:
inclusion criteria: * implanted with a functioning sjm quadripolar crt pacing system * qrs duration \> 140 ms * left bundle branch block documented * ability to provide informed consent for study participation * willing to comply with the study evaluation requirements * at least 18 years of age exclusion criteria: * crt pacing system implanted less than 1 week at time of enrollment * crt pacing system implanted more than 24 months at time of enrollment * crt pacing system implanted more than 90 days at time of enrollment and intrinsic qrs duration is shorter than pre-implant intrinsic qrs duration by more than 10 ms * resting ventricular rate \>100 bpm * intrinsic pr interval \> 300 ms * paroxysmal or persistent atrial tachycardia or atrial fibrillation documented * a recent myocardial infarction, ablation, drug intoxication, electrolyte imbalance, or any condition within the last 90 days that would be contraindicated for crt programming changes in the opinion of the investigator * women who are pregnant or who plan to become pregnant during the study
abbott brady 3t mri pmcf

Conditions: Syncope; Presyncope; Fatigue; Disorientation; Arrythmia; Bradycardia

Summary: the objective of this post-market, clinical follow up (pmcf) study, is to confirm the long-term safety of the tendril sts and isoflex leads, implanted with the assurity mri™ or endurity mri™ pacemakers, in patients undergoing a clinically indicated 3t mri (3 tesla magnetic resonance imaging) scan.

this prospective, non-randomized, observational study will be conducted at 35 centers worldwide where the study devices have 3t mr conditional labeling; up to 110 patients will be enrolled, and will satisfy the recent pmcf requirement to maintain the ce mark.

Eligibility criteria:
inclusion criteria: 1. subject must be willing and able to provide informed consent for study participation (legal guardian or legally authorized representative is not acceptable). 2. subject must be implanted with a st. jude medical tendril sts 2088 or isoflex 1944/1948 lead, and assurity mri or endurity mri pacemaker. 3. capture threshold is stable and \< 2.5v @ 0.5ms at the time of enrollment. 4. subject is clinically indicated for a 3t mri scan without sedation note: antianxiety agents (e.g. minor tranquilizers, etc.) may be used as long as the patient can communicate with site personnel during the mri scan 5. subject is willing and able to comply with the prescribed follow-up tests and schedule of evaluations. exclusion criteria: 1. the subject is currently participating in a clinical investigation that includes an active treatment arm that may confound the results of this study as determined by abbott. 2. the subject is \<18 years old (pediatric). 3. that subject has a life expectancy of less than 12 months due to any condition. 4. pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. 5. presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results. 6. any contraindication to mri scan, including the presence of additional hardware (e.g. lead extenders, lead adapters, surgical staples, stents, dental braces, or abandoned leads).

Keywords: 3 tesla mri
physiotherapy in the haemophilic arthropathy of the elbow.

Conditions: Patients With Hemophilia

Summary: the aim of this study is to assess the effectiveness of two treatments of physiotherapy: one with joint traction, passive muscles stretching and proprioceptive neuromuscular facilitation (pnf), and the other with education sessions and home exercises, for the improvement of the rom, biceps strength, perimeter of arm and the perception of pain in pwh and arthropathy of the elbow.

the intervention was carried out during twelve weeks, performing evaluations before and after treatment, and six months of finalizing this. the treatment of mt group consisted of two sessions per week, one hour each, and the treatment of group e consisted in a session for 90 minutes every two weeks, with daily home exercises. the control group (group c) did not receive any intervention.

Eligibility criteria:
inclusion criteria: * patients over 18 years * patients diagnosed with hemophilia a or b * patients with hemophilic arthropathy in one or both elbows exclusion criteria: * patients with another medical diagnosis (eg, von willebrand's disease) * patients with presence of antibodies to fviii or fix (inhibitors) * patients who had a haemarthrosis of elbow during the study

Keywords: elbow joint disease hemophilia physiotherapy modalities
study of postoperative cognitive decline in aged patients

Conditions: Cognitive Decline

Summary: postoperative cognitive decline is a common and deleterious complication in aged patients.the link between inflammation and postoperative cognitive decline has also been reported.however,the link between sod1，sod2，osteopontin， kallikrein-6，and contactin-1 and postoperative cognitive decline is unknown. in this project ,investigators examine the relationship between 5 cytokines measured at there timepoints (preoperative \[preop\], postoperative day 1 \[pod1\] , and postoperative day 3\[pod2\]) and postoperative cognitive decline among older adults undergoing orthopedic surgery.


Eligibility criteria:
inclusion criteria: * patients who are more than 65 years old * patients who undergo orthopedic surgery(trauma ,especially fracture of lower limb) * patients with asa physical status i-iii * patients who have a consent exclusion criteria: * patients who are more than 85 years old * patients with asa physical status \>iii * patients who have neurological disorders, stroke or other affective central nervous system diseases * patients who have a history of serious psychiatric illness * patients with long-term use of psychoactive substances * patients who undergo multiple trauma and the presence of head injury
a global study to assess the effects of durvalumab with oleclumab or durvalumab with monalizumab following concurrent chemoradiation in patients with stage iii unresectable non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this is a phase iii, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (medi4736) in combination with oleclumab (medi9447) or durvalumab (medi4736) with monalizumab (iph2201) in adults with locally advanced (stage iii), unresectable nsclc, who have not progressed following platinum-based ccrt.


Eligibility criteria:
inclusion criteria: * participant must be ≥ 18 years at the time of screening. * histologically- or cytologically-documented nsclc and have been treated with concurrent crt for locally advanced, unresectable (stage iii) disease * provision of a tumour tissue sample obtained prior to crt * documented tumour pd-l1 status by central lab * documented egfr and alk wild-type status (local or central). * patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy * participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy * participants must have received a total dose of radiation of 60 gy ±10% (54 gy to 66 gy) as part of the chemoradiation therapy, to be randomised. radiation therapy should be administered by intensity modulated rt (preferred) or 3d-conforming technique. * who performance status of 0 or 1 at randomization * adequate organ and marrow function exclusion criteria: * history of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or ta tumours without evidence of disease. * mixed small cell and non-small cell lung cancer histology. * participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (stage iii) unresectable nsclc. * participants with locally advanced (stage iii) unresectable nsclc who have progressed during platinum-based ccrt. * any unresolved toxicity ctcae \>grade 2 from the prior chemoradiation therapy (excluding alopecia). * participants with ≥grade 2 pneumonitis from prior chemoradiation therapy. * history of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. evidence of active non-crt induced pneumonitis (≥ grade 2), active pneumonia, active ild, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization. * active or prior documented autoimmune or inflammatory disorders (with exceptions) * current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.

Keywords: non-small cell lung cancer locally advanced nsclc
investigation of leukocyte trafficking into skin blisters during cardiopulmonary bypass

Conditions: Ischemic Heart Disease; Angina Pectoris

Summary: the purpose of this study was to see if the heart-lung machine involved in cardiac surgery increases the movement of activated white blood cells from the bloodstream into the patient's tissues and also to see if aprotinin usage during surgery reduces this effect.

it has long been known that exposure of blood to the heart-lung bypass machine can trigger a whole-body inflammatory response in cardiac surgery patients that is linked to activation of circulating white blood cells. the investigators propose to use a technique to track the movement of white blood cells into the skin of patients during bypass surgery. the skin blisters will be elicited by application of the blistering agent cantharidin to the forearm of volunteer patients. this will allow the investigators to study the activation state of white blood cells that enter tissues during bypass surgery and to determine whether aprotinin has any beneficial effect with regards to inflammatory status of these cells. the investigators propose that white blood cell trafficking into the blisters will increase following the use of the heart-lung machine and that the effect of aprotinin will be to ablate this.

Eligibility criteria:
inclusion criteria: * primary elective coronary artery bypass surgery exclusion criteria: * emergent, urgent or re-do surgery * patients on oral corticosteroid medication * patients on aspirin therapy \< 7 days prior to operation

Keywords: cardiopulmonary surgery leukocyte inflammation coronary artery bypass grafting
muscle fat compartments and turnover as determinant of insulin sensitivity

Conditions: Diabetes

Summary: early research found that high levels of fat within muscle meant poorer control of blood sugar. however, more recent research has shown that athletes have similar levels of fat within muscle, but in contrast, they have very good control of blood sugar. the investigators are not sure why this is and want to find out if the fat within muscle can be changed to improve blood sugar control, as good blood sugar control reduces the risk of heart disease, diabetes and stroke.

higher levels of triglycerides (tg) and diacylglycerols (dag) are found in skeletal muscle of patients with obesity/diabetes as well as in trained athletes. despite similar metabolic storage, patients and athletes have opposite insulin sensitivity phenotypes and an explanation for this is lacking. the investigators' objective is to understand how these fat compartments can be beneficially modulated to improve insulin resistance and cardio-metabolic risk. the investigators will investigate if either structural differences (saturated versus unsaturated balance of tg and dag side-chains) or different handling abilities (fast versus slow lipid pool turnover) will be induced by exercise capacity interventions in athletes and in diabetic patients. in a longitudinal study pre- and post-exercise, the investigators will use novel, non-invasive 1h-magnetic resonance spectroscopy to benchmark the saturated/unsaturated compartments against skeletal muscle biopsies for the first time and stable isotope analysis for fat compartments' rate of turnover.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients, aged between 20-65, diagnosed as per who criteria, diet controlled or diet and any of the following oral hypoglycemics: metformin, sulphonylureas, glitazones, gliptins, acarbose, but not requiring insulin for controlling of blood glucose. * trained, athletic healthy controls, aged 18 and over. * participant who is willing and able to give informed consent for participation in the study. * able to perform exercise testing. exclusion criteria: * any history of known coronary artery disease. * other endocrine conditions * impaired renal function defined as egfr\<60mls/min/1.73m2 * known resting/24 hour bp \>160/100mmhg * participants on ace inhibitors * participants on ppar agonists * participants on omega 3 fatty acids * the existence of any medical or surgical condition that in the judgement of the investigators may interfere with the exercise regime, fa metabolism or may compromise the safety of the subject * presence of other significant concomitant heart diseases such as ischaemic, valvular, pericardial heart disease or cardiomyopathy, skeletal muscle disorders * healthy volunteers that are on any chronic medication that in the judgment of the investigators is likely to affect the outcome of the study * significant asthma * significant pulmonary disease * participants unable to cycle on the ergometer * unable to perform exercise testing (e.g. prosthetic limbs)